准分子激光原位角膜磨镶术治疗混合性散光

目的:研究准分子激光原位角膜磨镶术治疗混合性散光的安全性和有效性。方法:采用Technolas217-Z准分子激光机,对9例(11眼)混合性散光患者进行手术,并随访0.5a以上,观察手术前后视力、屈光度、散光及散光轴的变化。结果:术后6mo裸眼视力10眼(91%)均等于或超过术前最佳矫正视力,术后球镜屈光度在±0.75D以内,残余散光度平均为–0.77±0.13D,散光轴向平均较术前偏斜3.15°±1.3°。结论:准分子激光原位角膜磨镶术治疗混合性散光安全、有效。     

VISX STAR S3准分子激光原位角膜磨镶术治疗高度近视疗效观察

目的 观察VISX STAR S3准分子激光系统原位角膜磨镶术(LASIK)治疗高度近视的疗效.方法 利用VISX STAR S3准分子激光仪对55人(108眼)高度近视患者(等值球镜-6.0D～-15.87D)行标准的LASIK手术,术后至少随访6月以上,用国际标准视力表检查记录术后裸眼视力(UCVA)和最佳矫正视力(BCVA),检查角膜地形图,并观察患者的主要症状及相关并发症.结果 在108只手术眼中,术前拟矫正等值球镜(SE)平均为(-8.15±1.68)D,实际矫正SE平均为(-7.91±1.95)D;术后残留屈光度在±0.5D以内者有81眼(75%),在±1.0D以内者有92眼(85.2%),±1.0D以上者14眼(12.9%);54%的术眼裸眼视力达到1.0以上,裸眼视力0.5以上者占99%;25.9%的患眼术后最佳矫正视力超过术前1行或更好,BCVA等于或超过术前者占84.3%,15.7%最好矫正视力下降1行,没有出现最佳矫正视力下降超过1行的情况.角膜地形图检查,有19.4%切削偏中心0.5mm以上,未发现继发性圆锥角膜或角膜扩张.至最后一次随访,11人(20%)主诉夜间视力下降或眩光.结论 VISX STAR S3准分子激光原位角膜磨镶术治疗-16D以下高度近视有很好的安全性和疗效,但仍会发生相当比例的偏中心切削和术后夜间视觉异常问题.     

准分子激光双面切削原位角膜磨镶术矫治后巩膜加固术后的高度近视疗效观察

目的:探讨准分子激光双面原位角膜磨镶术矫治后巩膜加固术后高度近视的有效性。方法:选择18例(36眼)后巩膜加固术后高度近视患者,屈光度数稳定1a以上,行准分子激光双面原位角膜磨镶术,观察其术后视力、屈光度的变化。结果:17例裸眼视力(uncorrectedvisualacuity,UCVA)达到或超过术前最佳矫正视力(bestcorrectedvisualacuity,BCVA),1例术后裸眼视力较术前最佳矫正视力下降1行。近视屈光度由术前-11.58±1.57D减小至术后3mo时-0.51±0.96D。结论:准分子激光双面切削原位角膜磨镶术矫治后巩膜加固术后高度近视具有可预测性、有效性和稳定性。     

准分子激光角膜原位磨镶术治疗高度近视合并中高度散光

目的:观察准分子激光原位角膜磨镶术(LASIK)治疗高度近视合并中高度散光的临床疗效。方法:采用准分子激光原位角膜磨镶术治疗43例(79眼)高度近视合并中高度散光患者,屈光度为-6.0～-15.5D,散光为-2.0～-5.0D。结果:术后随访6mo,裸眼视力≥术前矫正视力者占91%,屈光度在±0.75D以内者占86%,残留散光平均为-0.45D。结论:LASIK治疗高度近视伴中高度散光,效果明显,安全可靠。     

屈光性弱视患者行准分子激光原位角膜磨镶术疗效观察

目的评价准分子激光原位角膜磨镶术(LASIK)治疗屈光性弱视的有效性、安全性和可预测性。方法回顾性分析2003年2月～2005年4月经LASIK治疗的24例(39眼)屈光性弱视病历。术前最佳矫正视力(BCVA)0.25～0.5,平均0.43±0.09。术后随访3～24月,平均12月。结果术后3月,裸眼视力达0.5～0.8及1.0眼分别为64.10%和2.58%,平均0.55±0.19;最佳矫正视力达0.5～0.8及1.0眼分别为61.54%和17.95%,平均0.65±0.22。残余球镜度≤±0.5D及>±0.5～≤±1.0D眼分别为38.46%和17.95%,平均-0.43±1.61D;残余柱镜度≤±0.5D和>±0.5～≤±1.0D眼分别为30.77%和41.03%,平均(-0.75D,0.69D)。结论LASIK可有效矫正屈光性弱视的屈光度,有效提高视力,且具有良好的安全性和可预测性。     

LASIK治疗角膜穿通伤术后角膜散光的临床观察

目的探讨准分子激光在治疗角膜穿通伤后角膜散光的有效性和安全性.方法采用准分子激光原位角膜磨镶术治疗角膜穿通伤术后散光22例22眼,稳定半年以上,瘢痕在瞳孔区以外,术前散光度数在-2.25D～-4.75D,随访1年以上,并对其资料进行分析.结果术前裸眼视力均在0.1以下,术后均在0.5以上,术后12个月在0.8以上者85.32%.结论准分子激光原位角膜磨镶术治疗角膜穿通伤术后的散光疗效令人满意,可使患者获得较好的视觉效果,疗效确定,安全、可靠.     

LASIK治疗远视疗效分析

目的 探讨准分子激光原位角膜磨镶术治疗远视的临床疗效.方法 对25例48只眼远视患者进行准分子激光原位角膜磨镶术(laser in situ keratomileusis,LASIK),术前等效球镜屈光度为+1.00-+8.00D(+4.20±2.00)D,术后随访一年.结果 术后第1天.裸眼远视力与术前最佳矫正视力相当或下降≤2行,随时间推移远视力逐渐上升.术后1年,裸眼远视力≤0.5为25例48只眼(100%),裸眼远视力≥1.0为13例26只眼(52.0%),平均裸眼远视力0.85±0.28.裸眼近视力≥0.5为25例48只眼(100%),裸眼近视力≥1.0为19例38只眼(76%),平均裸眼近视力0.90±0.26.术后1年,屈光度-0.50-+0.50D占83.2%,+0.50-+1.00D占12.6%,+1.00-+2.40D占6.6%,平均屈光度(+0.75±1.55)D.术中术后无严重并发症.结论 采用LASIK治疗远视具有良好安全性、有效性和可预测性.     

准分子激光原位角膜磨镶术手术治疗超高度近视合并散光

目的观察准分子激光原位角膜磨镶术（LASIK）治疗超高度近视合并散光的临床效果。方法采用准分子激光原位角膜磨镶术治疗52例（101眼）超高度近视合并散光患者,球镜度-10.00D～-14.00D,散光-0.50～-4.50DC。结果术后1天、1、3、6月裸眼视力与术前预期最佳矫正视力符合率分别为78.2%、85.1%、92.1%、87.1%;术后6个月,实际矫正屈光度与术前预期矫正符合率球镜93.1%、柱镜87.1%。结论LASIK治疗超高度近视合并散光,视力恢复快,安全可靠。     

选择不同的准分子激光手术矫治中高度近视散光的效果分析

目的探讨准分子激光原位角膜磨镶术（LASIK）和准分子激光上皮瓣下磨镶术（LASEK）治疗中高度散光的安全性和有效性。方法应用德国Asclepion-MeditecAG公司MEL70G-Scan准分子激光治疗系统对90例（133眼）中高度散光分别选用LASIK或LASEK进行治疗。随访3年以上,观察手术前后的视力、屈光度、散光及其散光轴位的变化。结果术后随访3年以上,裸眼视力≥术前最佳矫正视力者占86.46%,术后残留散光度在±1.00D以内者占90.23%,残留散光平均为-0.57D,两种术式的患者术后散光度均明显下降且均未见术中及术后并发症。结论 LASIK及LASEK手术治疗中高度散光并发症少,手术预测性好,均为安全、有效的屈光手术。     

Q值调整个性化在LASIK治疗中高度散光效果分析

目的 探讨Q值调整的个性化准分子激光原位角膜磨镶术(F-CAT)治疗中高度散光的安全性和有效性.方法 采用德国Wavelight公司的鹰视酷眼准分子激光系统,对36例(53只眼)中高度散光进行F-CAT手术治疗,术前等值柱镜度数-2.00～-6.00D,平均(-2.65±0.93)D.结果 术后12个月的平均裸眼视力为1.01±0.24,裸眼视力达到或超过术前矫正视力48只眼(90.6%).术后散光度较术前明显改善,除2只眼因角膜厚度所限,分别残留-1.5D、-1.75D散光,其余患者术后1年复查散光度均＜1 D,且一直较为稳定.术前Q值介于-0.05～-0.50,其中Q1值-0.29±0.10,Q2值0.33±0.12.目标Q值-0.15～-0.45,平均-0.29±0.09.术后12月角膜中央30度范围内Q值与术前球镜和柱镜之和相关性较强 .结论 F-CAT治疗中高度散光安全有效,视觉质量较好.     

飞秒激光制作角膜瓣的激光角膜原位磨镶术的临床观察

目的探讨应用飞秒激光制作角膜瓣的准分子激光角膜原位磨镶术（LASIK）的安全性、有效性和可预测性。方法应用VISX Stars 4准分子激光设备和Intralase飞秒激光仪,对屈光不正512例（1016眼）施行飞秒激光制作角膜瓣的LASIK手术。术后随访6～12个月,裂隙灯显微镜及角膜地形图仪检查角膜及角膜屈光改变情况。结果术后6个月的屈光状态,（等效球镜）为（1．00D～＋1．25D）,平均为（-0．25±0．75D）。923眼（90．85％）的裸眼视力大于或等于1．0,1002眼（98．62％）的裸眼视力等于或超过术前最佳矫正视力。术前与术后结果行t检验显示,二者差异有统计学意义（P〈0．01）。术中并发症有结膜下出血57眼（5．61％）,未见其他并发症。结论应用飞秒激光制作角膜瓣的LASIK手术是矫正屈光不正的安全和有效的方法,可预测性好。     

Laser-assisted subepithelial keratectomy for low to high myopia and astigmatism

PURPOSE: To evaluate the safety and efficacy of laser-assisted subepithelial keratectomy (LASEK) for the treatment of low to high myopia and astigmatism. SETTING: Solo private practice, Mountain View, California, USA. METHODS: Laser-assisted subepithelial keratectomy was performed in 146 eyes of 83 consecutive patients with myopia or myopic astigmatism using a VISX Star S2 excimer laser (72 eyes) or a Nidek EC-5000 excimer laser (74 eyes). The mean preoperative myopic spherical equivalent was -5.32 diopters (D) (range -1.25 to -14.38 D). Data were collected prospectively with a follow-up of 1 to 12 months. Outcome measurements included uncorrected visual acuity (UCVA), manifest refraction, best spectacle-corrected visual acuity (BSCVA), corneal haze, and complications. RESULTS: After 6 and 12 months, no eye lost 2 or more lines of BSCVA. After 6 months, the UCVA was 20/20 in 57% of eyes and 20/40 or better in 96%. After 12 months, it was 20/20 in 56% of eyes and 20/40 or better in 96%. No eye developed corneal haze that affected visual acuity. There were no serious or vision-threatening complications. CONCLUSIONS: Laser-assisted subepithelial keratectomy was safe and effective in treating a wide range of myopia and astigmatism. The potential advantages of LASEK over laser in situ keratomileusis (LASIK) include the elimination of stromal flap complications and greater choice in patient selection. The disadvantages include varying degrees of pain for 2 days and blurry vision for several days postoperatively.     

Laser in situ keratomileusis for compound myopic astigmatism using the Meditec MEL 70 G-Scan excimer laser

PURPOSE: To determine the safety, efficacy, predictability, and stability of laser in situ keratomileusis (LASIK) in treating patients with myopic astigmatism using the Meditec MEL 70 G-Scan excimer laser. METHODS: Seventy-four eyes of 42 patients with myopia ranging from -4.50 to -9.88 D and astigmatism ranging from 0.50 to 4.00 D who underwent LASIK with the Meditec MEL 70 G-Scan excimer laser and the Summit Krumeich-Barraquer microkeratome were studied. Patients were followed for 1 year. RESULTS: Mean baseline spherical equivalent refraction was -7.12 +/- 1.70 D and cylinder was 1.62 +/- 1.72 D. At 12 months, mean postoperative spherical equivalent refraction was -0.49 +/- 0.57 D and mean refractive cylinder was 0.59 +/- 0.32 D. Mean change in spherical equivalent refraction between 1 and 12 months after surgery was -0.09 +/- 0.31 D, toward myopia. At baseline, no eyes had best spectacle-corrected visual acuity (BSCVA) of 20/20 or better, and 65% had 20/40 or better. At 12 months after surgery, 10% of eyes had BSCVA of 20/20 or better and 88% of eyes had 20/40 or better. The unusually low postoperative BSCVA results were thought to be due to amblyopia or existence of a higher percentage of some optical aberrations in this group of eyes. Mean uncorrected visual acuity was -1.38 +/- 0.42 LogMAR units (20/400) at baseline and -0.29 +/- 0.25 LogMAR units (20/40) at the 12-month postoperative examination. No eyes lost two or more lines of spectacle-corrected visual acuity. No vision threatening complications were observed. CONCLUSIONS: LASIK with the Meditec MEL 70 G-Scan excimer laser appeared to be safe, effective, reasonably predictable, and stable for correction of myopic astigmatism with a spherical component between -4.25 and -8.25 D and a cylindrical component between 0.50 and 4.00 D. However, astigmatism was slightly undercorrected with the algorithm used.     

Comparison of the toric implantable collamer lens and custom ablation LASIK for myopic astigmatism

PURPOSE: To compare the results of wavefront-guided custom LASIK and the Toric Implantable Collamer Lens (TICL) in the correction of myopic astigmatism. METHODS: This observational, non-randomized study compared clinical efficacy results from the TICL's US Food and Drug Administration Clinical Trial and published Summaries of Safety and Effectiveness of two wavefront-guided lasers: STAR S4 CustomVue excimer laser system (VISX Inc) and LADARVision4000 CustomCornea excimer laser system (Alcon Laboratories Inc). Preoperative myopic refractive error was divided into two groups: -3.00 to -7.00 diopters (D) and -7.00 to -11.00 D. RESULTS: The percentage of eyes with uncorrected visual acuity (UCVA) of 20/20 and 20/40 and predictability of manifest refraction spherical equivalent within +/- 0.50 and +/- 1.00 D in the three groups was similar with only one statistically significant difference (TICL versus Alcon within +/- 1.00 D: 97% versus 82%; P = .008). The TICL had significantly better postoperative best spectacle-corrected visual acuity (BSCVA) compared to preoperative BSCVA than both the VISX CustomVue and Alcon CustomCornea (P < .001). The TICL postoperative UCVA outcomes compared to preoperative BSCVA were significantly better than Alcon CustomCornea outcomes (P < .001). Additionally, almost half (48%) of the TICL cases had improvement in postoperative UCVA compared to preoperative BSCVA, whereas only 23% of the Alcon CustomCornea eyes showed improvement. CONCLUSIONS: Although comparable in clinical efficacy outcomes, the TICL had a significantly better postoperative improvement in BSCVA and significantly better postoperative UCVA than preoperative BSCVA. The TICL can be considered as an alternative to LASIK through the full range of use.     

Nomogram adjustment of laser in situ keratomileusis for myopia and myopic astigmatism with the Alcon LADARVision system

PURPOSE: To evaluate the visual and refractive results of conventional (non-wavefront) laser in situ keratomileusis (LASIK) for treatment of myopia and myopic astigmatism using the Alcon LADARVision 4000 excimer laser system and nomogram adjustment techniques. METHODS: A retrospective analysis of 499 eyes that had LASIK for myopia and myopic astigmatism was performed. Preoperative manifest spherical equivalent refraction ranged from -0.43 to -6.00 D and preoperative astigmatism ranged from 0 to -4.75 D. Patients were evaluated during 3 months following surgery. RESULTS: One month after surgery, 72% of eyes examined (298/415 eyes) had uncorrected visual acuity (UCVA) of 20/20 or better. Three months after surgery, 83% of eyes examined (216/261 eyes) had UCVA of 20/20 or better. One and three months after surgery, 82% and 83% of eyes, respectively, were within +/-0.50 D of attempted correction; 97% of eyes were within +/-1.00 D at both 1 and 3 months. No eye lost more than 1 line of best spectacle-corrected visual acuity (BSCVA) at 3 months after surgery. At the 3-month examination, 83% of eyes had UCVA better than or equal to preoperative BSCVA. CONCLUSIONS: Conventional LASIK to correct myopia and myopic astigmatism was safe and effective using the Alcon LADARVision 4000 excimer laser system. Outcomes were substantially improved throughout development of an accurate nomogram, derived from continually updated regression analysis of previous refractive results.     

Topographic centration of ablation after LASIK for myopia using the CustomVue VISX S4 excimer laser

PURPOSE: To determine the ablation centration, efficacy, predictability, and safety of CustomVue LASIK using the VISX S4 excimer laser for the treatment of myopia and myopic astigmatism. METHODS: A retrospective review of 20 myopic eyes of 12 patients treated with LASIK CustomVue VISX S4 was conducted. Corneal topography was used to determine ablation centration. Primary outcome variables including manifest refraction, best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA), and complications were evaluated at 3 months postoperatively. RESULTS: Mean decentration (from ablation zone to entrance pupil) was 0.23 +/- 0.08 mm at 3 months postoperatively. No eyes were decentered > 0.5 mm. Preoperatively, the mean spherical equivalent refraction was -4.81 +/- 11.39 diopters (D) (range: -6.75 to -2.25 D). At 3 months postoperatively, mean spherical equivalent refraction was -0.63 +/- 0.25 D (range: -2.00 to 0.25 D). Nineteen (95%) of 20 eyes had UCVA of 20/40 and 16 (80%) of 20 eyes had UCVA of 20/20 at 3 months postoperatively. Fourteen (70%) eyes were within +/- 0.50 D and 18 (90%) eyes were within +/- 1.00 D of emmetropia. No eye lost > 1 line of BSCVA. CONCLUSIONS: Wavefront-guided LASIK using the CustomVue VISX S4 for myopic eyes results in minimal decentration ablation and effective, predictable, and safe visual outcomes.     

Laser in situ keratomileusis for high myopia with the VISX star laser

PURPOSE: To evaluate the results of laser in situ keratomileusis (LASIK) for spherical and spherocylindrical myopia (range, 9-22 diopters [D]) with the VISX Star laser, (VISX Inc., Santa Clara, CA). DESIGN: Non-comparative, single-surgeon interventional case series. PARTICIPANTS: Two hundred ninety eyes of 175 patients. METHODS: Consecutive patients who underwent LASIK in the study range with the VISX Star laser were evaluated for early (approximately 1 month) and late (after 9 months) outcomes. Both single procedure outcomes and results after reoperation for refractive enhancement were included. MAIN OUTCOME MEASURES: Outcome measures included uncorrected visual acuity, manifest refraction, refractive predictability, refractive stability, best spectacle-corrected visual acuity (BSCVA), results of reoperations, and complications. RESULTS: At the early postoperative examination, approximately 1 month after surgery, 285 of 290 eyes (98.3%) were examined. Uncorrected visual acuity of 20/40 or better occurred in 209 of 285 (73.3%) eyes, and 198 of 285 (69.5%) eyes had a manifest spheroequivalent between +/-1.00 D. Subsequently, 60 eyes (20.7%) underwent reoperation for refractive enhancement. Late results, beyond 8 months from the initial surgery and including reoperations, were available in 195 of 290 eyes (67.2%). Uncorrected visual acuity results of 20/40 or better were found in 166 of 195 eyes (85.1%) and of 20/25 or better in 99 of 195 eyes (50.8%). Manifest spheroequivalent results were +/-2.00 D in 187 of 195 eyes (95.9%) and +/-1.00 D in 148 of 195 eyes (75.9%). In a paired-cohort analysis of 131 single-procedure eyes seen at both intervals, refractive stability (change in manifest refractive spheroequivalent of less than 1.00 D) was present in 101 of 131 eyes (77.1%) between the two observation intervals. Overall, approximately 3.6% eyes lost 2 lines or more of BSCVA, and other complications (flap wrinkling and epithelial ingrowth) were reported in 2% of eyes. Improvement in BSCVA of 1 line or more occurred in 5.6% eyes. CONCLUSIONS: Laser in situ keratomileusis for high myopia with the VISX Star laser provided satisfactory refractive and visual results that compare well with other reports in the literature. Subjective results and other measures of visual function need further evaluation.     

Toric laser in situ keratomileusis for myopic astigmatism using an ablatable mask

BACKGROUND: To assess the results of toric laser in situ keratomileusis (LASIK) correction of myopic astigmatism. METHODS: A prospective study was performed over a 20 week period for consecutive patients treated for myopic astigmatism. Spectacle-corrected visual acuity, uncorrected visual acuity, spectacle refraction, videokeratography, and complications were recorded. Vector analysis was performed by the ASSORT program. RESULTS: Sixty-five eyes of 42 patients underwent toric LASIK with a Summit Technologies Apex Plus excimer laser. Mean preoperative spherical equivalent refraction at the spectacle plane was -6.24 +/- 2.42 D (range, -1.63 to -14.63 D) and mean pre-operative refractive cylinder magnitude was 1.99 +/- 1.35 D (range, 0.75 to 7.00 D); mean attempted refractive cylinder correction was 1.90 +/- 1.00 D. Six months after LASIK (43 eyes followed), mean spherical equivalent refraction at the spectacle plane was -0.40 +/- 0.55 D and 31 eyes (72.1%) were within +/- 0.50 D of emmetropia. At 6 months, mean refractive cylinder magnitude was 0.74 +/- 0.70 D, mean surgically induced astigmatism was 1.46 +/- 0.86 D, mean absolute angle of error was 10.33 degrees, mean astigmatic correction index was 0.93 +/- 0.36 D, and mean index of success was 0.46 +/- 0.39. Uncorrected visual acuity was 6/12 or better in 34 eyes (79.1%) and 6/6 in 15 eyes (35%); spectacle- corrected visual acuity was 6/9 or better in 41 eyes (95.35%). Six eyes (14.0%) lost 1 line of spectacle-corrected visual acuity at 6 months and one eye (2.3%) lost 2 lines. Ten eyes (23.3%) gained 1 line at 6 months. CONCLUSION: Toric LASIK with an ablatable mask using the Summit Apex Plus excimer laser is a safe and relatively accurate procedure for the correction of myopic astigmatism.     

Ten-year follow-up of laser in situ keratomileusis for high myopia

PURPOSE: To evaluate the long-term outcomes of laser in situ keratomileusis (LASIK) for high myopia. DESIGN: A long-term (10 years) follow-up retrospective interventional case series study. METHODS: The study included 196 myopic eyes of 118 patients with a mean preoperative spherical equivalent of -13.95 +/- 2.79 diopter (D) treated with myopic LASIK at the Instituto Oftalmológico de Alicante, Spain using the VISX 20/20 excimer laser (VISX Inc, Santa Monica, California, USA) and the Automated Corneal Shaper microkeratome (Chiron Vision, Irvine, California, USA). All patients were evaluated three months, one year, two years, five years, and 10 years postoperatively. The main outcome measures were refractive predictability and stability, mean corneal keratometry, topographical cylinder, safety, efficacy, stability of visual acuity, and postoperative complications. RESULTS: At 10 years, 82 (42%) of 196 eyes were within +/-1.00 D and 119 (61%) were within +/-2.00 D. Fifty-four (27.5%) eyes underwent retreatments attributable to under correction and/or regression. The myopic regression decreases with time in eyes that did not undergo retreatment with a mean rate of -0.25 +/- 0.18 D per year. Eleven eyes (5%) lost more than 2 lines of best spectacle-corrected visual acuity (BSCVA) and 78 eyes (40%) showed a postoperatively uncorrected visual acuity of 20/40 or better. Two eyes (1%) with more than 15 D myopic correction developed corneal ectasia. CONCLUSIONS: LASIK for myopia over -10 D is a safe procedure with myopic regression that slows down with time and a high rate of BSCVA increase in the long-term.     

准分子激光原位角膜磨镶技术分步多区切削治疗高度近视的疗效分析

目的:探讨准分子激光原位角膜磨镶技术(laser in situker-atomileusis,LASIK)治疗高度近视的疗效。方法:应用日本Nidek EC5000Ⅱ准分子激光仪,采用多步分区切削法治疗高度近视。按屈光度分为两组,I组:-6.00～-9.00D,128眼;II组:-9.00～-14.00D,147眼。术后随访1a,并对结果进行分析。结果:两组患者术后1a裸眼视力≥0.6者占89.6%,≥1.0者占55.6%(其中I组≥0.6者占95.1%,Ⅱ组≥0.6者占88.9%)。术后最佳矫正视力大于术前者占38.1%,小于术前者占6.0%,94.0%术后最佳矫正视力不变或上升。术后1a实际矫正度在预测矫正度±1.00D内者占81.3%,±2.00D内者占90.2%。激素性高眼压占0.04%。结论:准分子激光原位角膜磨镶技术多步分区切削法治疗高度近视伴薄角膜及超高度近视是一种安全、有效,且稳定性较好的方法,能有效预防屈光回退的发生,同时可以减少术后眩光和暗视力下降等现象。